Clareo Health | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
1. Has ESKD and has regular adherence receiving HD 3 times per week as described in the protocol
2. Is receiving heparin (standard of care) anticoagulation, with no history of intolerability, during each dialysis session
3. Has adequate vascular access
4. Is clinically stable with no hospitalizations in the past 30 days prior to first screening visit as described in the protocol
You may not be if
1. Has history of major bleeding (International Society on Thrombosis and Haemostasis \[ISTH\]) criteria) within the past 3 months prior to the first screening visit as described in the protocol
2. Has known bleeding conditions (eg, Hemophilia A, B or C, von Willebrand's disease) hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
3. Current use of oral anticoagulants (eg, warfarin, Direct Oral Anti-Coagulant \[DOACs\]) or dual antiplatelet therapy for clinical indication
4. Heart failure as classified by New York Heart Association (NYHA) class III or IV
5. Has a sustained uncontrolled hypertension as described in the protocol
